A CHEK1 inhibitor, LY2606369, is currently used in clinical trials for breast cancer patients with BRCA1/2 mutations and could be re-purposed for treating pleural mesothelioma malignancy. The gene discussed is CHEK1; the disease is pleural mesothelioma.